PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO) (Paris:BIO), a company dedicated to specialty and orphan oncology products, today announces the initiation of the clinical batches production of Livatag® (doxorubicin Transdrug™) for its phase III clinical trial in primary liver cancer.
